![]() F-star Biotechnology F-star is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology. | ![]() Actinium Pharmaceuticals Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers. | ![]() Aceragen Aceragen (formerly known as Idera Pharmaceuticals) is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates. | |
Founding Date | Founding Date 2006 | Founding Date 2000 | Founding Date 1989 |
Type | Type Private | Type Public | Type Public |
Tags | |||
Locations | Locations Cambridge, GB HQ Wien, AT Cambridge, US | Locations New York, US HQ | Locations Durham, US HQ |
Employees | Employees 39 | Employees 2517% decrease | Employees 3642% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 58.6 m | Valuation ($) 3.2 m |
Financial | |||
Revenue (est.) | Revenue (est.) £18.7m (FY, 2018) | Revenue (est.) $90k (FY, 2025) | Revenue (est.) $4.9m (FY, 2022) |
Net income | Net income (£2.6m) (FY, 2018) | Net income N/A | Net income ($23.4m) (FY, 2022) |
Funding | |||
Total funding raised | Total funding raised $ 57.3m | Total funding raised $ 7m | Total funding raised $ 13.8m |

Actinium Pharmaceuticals is a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers.
View company
Aceragen (formerly known as Idera Pharmaceuticals) is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
View company